Campbell Soup Co. (NYSE: CPB) shares saw a nice bounce on Tuesday after activist investor Dan Loeb was said to be shaking things up. Loeb’s message seems pretty simple and is an appropriate measure considering the direction in which the soup maker has been headed recently.
Campbell’s stock has been in free fall for the past year. This was a $60 stock as recently as February 2017, and it has hit lows not seen in over five years in the past two weeks. The stock has only now just recovered from mid-May when it last reported earnings and its CEO resigned.
Like every other activist investor — with the exception of maybe Bill Ackman — Loeb sees the company as undervalued and is petitioning the board to do something about it.
According to the New York Post, Loeb’s Third Point hedge fund is in talks with family members who control roughly 41% of Campbell’s shares and with independent Campbell investors about supporting a plan that would result in hiring a bank to explore a possible sale of the 149-year-old company. This comes from two sources close to the situation, said the New York Post.
Best Undervalued Stocks To Own For 2019: CEVA, Inc.(CEVA)
Advisors’ Opinion:
- [By Joseph Griffin]
Piedmont Investment Advisors LLC bought a new stake in shares of CEVA, Inc. (NASDAQ:CEVA) during the 2nd quarter, according to its most recent filing with the SEC. The fund bought 5,175 shares of the semiconductor company’s stock, valued at approximately $156,000.
- [By Shane Hupp]
CEVA, Inc. (NASDAQ:CEVA)’s share price reached a new 52-week low during trading on Thursday . The stock traded as low as $24.70 and last traded at $24.72, with a volume of 4834 shares traded. The stock had previously closed at $24.81.
- [By Stephan Byrd]
SuperCom (NASDAQ:SPCB) and CEVA (NASDAQ:CEVA) are both small-cap industrial products companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk and analyst recommendations.
- [By Stephan Byrd]
Rhumbline Advisers lifted its position in shares of CEVA, Inc. (NASDAQ:CEVA) by 4.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 53,568 shares of the semiconductor company’s stock after acquiring an additional 2,184 shares during the period. Rhumbline Advisers owned approximately 0.24% of CEVA worth $1,618,000 as of its most recent filing with the Securities & Exchange Commission.
- [By Lisa Levin]
CEVA, Inc. (NASDAQ: CEVA) was down, falling around 12 percent to $30.25 after the company posted weaker-than-expected Q1 profit.
Commodities
Best Undervalued Stocks To Own For 2019: National Steel Corporation(SID)
Advisors’ Opinion:
- [By Rich Smith]
Brazilian steelmaker Companhia Siderurgica Nacional (NYSE:SID) stock lost 20% of its value in last month’s sell-off, hurt by a shareholder dispute with management and (probably) continued generally negative sentiment regarding South American stocks. This morning, however, shares of CSN are turning around, and trading up 13% as of 12:30 p.m. EDT.
- [By Ethan Ryder]
Companhia Siderurgica Nacional (NYSE:SID) shares gapped up prior to trading on Tuesday . The stock had previously closed at $2.52, but opened at $2.53. Companhia Siderurgica Nacional shares last traded at $2.58, with a volume of 90440 shares changing hands.
- [By Stephan Byrd]
Companhia Siderurgica Nacional (NYSE:SID)’s share price hit a new 52-week low during trading on Tuesday . The company traded as low as $1.95 and last traded at $1.99, with a volume of 131251 shares. The stock had previously closed at $2.02.
- [By Rich Smith]
Confirming that this was not an “oil story” but a “Brazil story,” shares of Brazilian airline Azul SA (NYSE:AZUL) and Brazilian steel company Companhia Siderurgica Nacional (NYSE:SID) likewise declined steeply — closing down 7.2% and 4.8%, respectively. Overall, the Brazilian Ibovespa benchmark stock index closed down 3.7%, after falling as much as 6% in trading earlier in the day.
Best Undervalued Stocks To Own For 2019: UTStarcom Holdings Corp(UTSI)
Advisors’ Opinion:
- [By Joseph Griffin]
ADVA Optical Networking (OTCMKTS: ADVOF) and UTStarcom (NASDAQ:UTSI) are both small-cap computer and technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership and valuation.
- [By Logan Wallace]
TheStreet cut shares of UTStarcom (NASDAQ:UTSI) from a c rating to a d+ rating in a report issued on Monday morning.
UTStarcom opened at $4.93 on Monday, MarketBeat reports. UTStarcom has a 52-week low of $4.95 and a 52-week high of $4.99.
- [By Stephan Byrd]
Iteris (NASDAQ: ITI) and UTStarcom (NASDAQ:UTSI) are both small-cap computer and technology companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability and analyst recommendations.
- [By Max Byerly]
ADVA Optical Networking (OTCMKTS: ADVOF) and UTStarcom (NASDAQ:UTSI) are both small-cap computer and technology companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk.
Best Undervalued Stocks To Own For 2019: Blueprint Medicines Corporation(BPMC)
Advisors’ Opinion:
- [By Todd Campbell]
In this clip of The Motley Fool’s Industry Focus Healthcare, host Kristine Harjes is joined by Motley Fool contributor Todd Campbell to discuss LOXO-292’s opportunity and how competitor Blueprint Medicines (NASDAQ:BPMC) is challenging it. Also, the two analysts discuss why shares in Abiomed, Inc. (NASDAQ:ABMD) are soaring higher and if this is a high-priced stock that investors should embrace or ignore.
- [By Ethan Ryder]
Shares of Blueprint Medicines Corp (NASDAQ:BPMC) have received an average recommendation of “Buy” from the thirteen research firms that are presently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $92.22.
- [By Todd Campbell]
Investors should also keep their enthusiasm in check because Loxo Oncology isn’t alone in targeting TRK fusion and RET mutations: Roche Holdings (NASDAQOTH:RHHBY) could challenge it in TRK fusions and Blueprint Medicines (NASDAQ:BPMC) could compete with it in RET mutations.
- [By Brian Orelli]
On the downside, Blueprint Medicines (NASDAQ:BPMC) also is developing a RET targeting drug called BLU-667. The company doesn’t seem to be presenting additional data at ASCO, likely because it just released data last month at the American Association for Cancer Research meeting. While it’s very hard to make apples-to-apples comparisons across phase 1 trials, BLU-667 doesn’t look quite as active, with ORR of 50% percent in patients with NSCLC and 40% in patients with medullary thyroid cancer.
- [By Todd Campbell]
The big thing to watch this week will be how investors view Loxo’s results in comparison to results presented earlier this year by Blueprint Medicines (NASDAQ:BPMC). Blueprint’s BLU-667 also targets RET-fusions and at the American Association for Cancer Research meeting in April, Blueprint revealed a preliminary overall response rate of 50% for NSCLC and 40% for MTC. It’s bad science to compare unrelated trials, so investors might be best off viewing Loxo and Blueprint’s data as evidence that they’re both working on a winning approach.
Best Undervalued Stocks To Own For 2019: Qorvo, Inc.(QRVO)
Advisors’ Opinion:
- [By Harsh Chauhan]
Investors didn’t waste any time expressing their disappointment after Qorvo’s (NASDAQ:QRVO) fourth-quarter 2018 results came out. The chipmaker failed to offer strong guidance for the current quarter, which was enough to blind investors to the fact that it did well to turn its business around to some extent in the previous quarter.
- [By Ethan Ryder]
American International Group Inc. raised its position in shares of Qorvo (NASDAQ:QRVO) by 4.1% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 47,585 shares of the semiconductor company’s stock after purchasing an additional 1,880 shares during the period. American International Group Inc.’s holdings in Qorvo were worth $3,352,000 at the end of the most recent reporting period.
- [By Jon C. Ogg]
Qorvo Inc. (NASDAQ: QRVO) was raised to Overweight from Sector Weight with a $95 price target (versus a $77.44 close) at KeyBanc Capital Markets.
Valeritas Holdings Inc. (NASDAQ: VLRX) was started as Outperform and assigned a $3.50 price target (versus a $1.35 close) at Oppenheimer. Valeritas was indicated up over 6% at $1.44 on Thursday morning, but this is a microcap stock.
- [By Ezra Schwarzbaum]
Several other optics stocks stand to gain. In a Monday note, Bank of America Merrill Lynch analyst Vivek Arya also highlighlited the semiconductor space as one that could benefit from the news. Other stocks to watch include:
Lumentum Holdings Inc (NASDAQ: LITE)
Ciena Corporation (NYSE: CIEN)
Coherent, Inc. (NASDAQ: COHR)
II-VI, Inc. (NASDAQ: IIVI)
Inphi Corporation (NYSE: IPHI)
Skyworks Solutions Inc (NASDAQ: SWKS)
Integrated Device Technology Inc (NASDAQ: IDTI)
Qorvo Inc (NASDAQ: QRVO)
Xilinx, Inc. (NASDAQ: XLNX)
Broadcom Inc (NASDAQ: AVGO)Related Links: